<DOC>
	<DOCNO>NCT02791334</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability anti-programmed cell death ligand 1 ( PD-L1 ) checkpoint antibody LY3300054 participant advance refractory solid tumor .</brief_summary>
	<brief_title>A Study Anti-PD-L1 Checkpoint Antibody ( LY3300054 ) Alone Combination Participants With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Histologic cytologic confirmation advance solid tumor . For monotherapy , prior treatment PD1 PDL1 agent allow . For LY3300054 combination therapy , previous immunotherapy acceptable , follow criterion meet : Must experience toxicity lead permanent discontinuation prior immunotherapy . Must completely recover recovered baseline prior screen prior adverse event ( AEs ) occur receive prior immunotherapy . Must experience Grade ≥3 immunerelated AE immunerelated neurologic ocular AE grade receive prior immunotherapy . Must require use additional immunosuppressive agent corticosteroids management AE , experience recurrence AE rechallenged , currently require maintenance dos &gt; 10 milligram prednisone equivalent per day . Have least 1 measurable lesion assessable use standard technique Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 . Have adequate organ function . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have submit tumor tissue sample , follow : For participant enter Phase 1a dose escalation : submit , available , archival tumor tissue sample . For participant participate ONLY Phase 1b expansion : submit tissue sample either newly obtain core excisional biopsy tumor lesion recent biopsy , define ≤3 year since last documented progression disease . Have estimate life expectancy ≥12 week , judgment investigator . Have serious concomitant systemic disorder include human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) , active hepatitis C virus ( HCV ) , active autoimmune disorder disease require high dose steroid . Have bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection chronic diarrhea . Have evidence interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity active , noninfectious pneumonitis . Have active infection require systemic therapy . Have moderate severe cardiovascular disease . Have symptomatic uncontrolled brain metastasis , spinal cord compression , leptomeningeal disease require concurrent treatment . Have receive live vaccine within 30 day first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>